Peptide delivery articles from across Nature Portfolio

Profiling antibody responses to vast antigenic spaces has been challenging using programmable phage display (PhIP-Seq). Here, authors develop a methodology for compressing large proteomic spaces and have discovered human antibodies targeting gut bacteria-infecting phages.

The ongoing emergence of highly pathogenic viruses that evade immune-based therapies or lack interventions mandates new approaches, especially for on-demand prophylaxis. Here the authors provide a stapled lipopeptide platform for the rapid development of viral fusion inhibitors to combat outbreaks.

A cancer vaccine is delivered to the lung by an engineered attenuated influenza virus.

Sustained drug delivery is critical for patient adherence to chronic disease treatments. Here the authors apply machine learning to engineer multifunctional peptides with high melanin binding, high cell-penetration, and low cytotoxicity, enhancing the duration and efficacy of peptide-drug conjugates for sustained ocular delivery.

A curvature-sensing peptide is used to disrupt exosomes for enhanced cancer immunotherapy.

The fusion of an immunogenic peptide and the protein transthyretin protects the peptide antigen from proteolytic degradation, optimizes its uptake in local draining lymphatics and reduces its presentation in uninflamed distal lymphoid organs, as shown in mice.

An amphipathic peptide has been engineered and is capable of penetrating the blood–brain barrier as well as possessing a potent antiviral activity against Zika and other mosquito-borne viruses.

A study demonstrates that controlled integrin binding on a biomaterial was capable of promoting vascular cell sprouting and formation of a non-leaky blood vessel network in a healthy and diseased state.

Intracellular protein delivery has been a major challenge in the field of cell biology for decades. Engineering such delivery is a key step in the development of protein- and antibody-based therapeutics. Now, two different approaches that enable the delivery of antibodies and antibody fragments into the cytosol have been developed.

A subcutaneous depot of a diabetes drug fused to a thermosensitive biopolymer leads to blood-glucose control, for over one week after a single injection, in animal models of type-2 diabetes.